Seguir
Rebecca S. Cook
Rebecca S. Cook
Associate Professor of Biomedical Engineering, Vanderbilt University
Dirección de correo verificada de vanderbilt.edu
Título
Citado por
Citado por
Año
Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases
RS Muraoka, N Dumont, CA Ritter, TC Dugger, DM Brantley, J Chen, ...
The Journal of clinical investigation 109 (12), 1551-1559, 2002
6792002
TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer
NE Bhola, JM Balko, TC Dugger, MG Kuba, V Sánchez, M Sanders, ...
The Journal of clinical investigation 123 (3), 1348-1358, 2013
6382013
Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets
JM Balko, JM Giltnane, K Wang, LJ Schwarz, CD Young, RS Cook, ...
Cancer discovery 4 (2), 232-245, 2014
5492014
RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune …
S Loi, S Dushyanthen, PA Beavis, R Salgado, C Denkert, P Savas, ...
Clinical Cancer Research 22 (6), 1499-1509, 2016
5382016
Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
JT Garrett, MG Olivares, C Rinehart, ND Granja-Ingram, V Sánchez, ...
Proceedings of the National Academy of Sciences 108 (12), 5021-5026, 2011
5182011
mTORC1 and mTORC2 in cancer and the tumor microenvironment
LC Kim, RS Cook, J Chen
Oncogene 36 (16), 2191-2201, 2017
4212017
MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors
AB Turke, Y Song, C Costa, R Cook, CL Arteaga, JM Asara, JA Engelman
Cancer research 72 (13), 3228-3237, 2012
4062012
Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo
DM Brantley, N Cheng, EJ Thompson, Q Lin, RA Brekken, PE Thorpe, ...
Oncogene 21 (46), 7011-7026, 2002
4062002
Biological consequences of MHC-II expression by tumor cells in cancer
ML Axelrod, RS Cook, DB Johnson, JM Balko
Clinical cancer research 25 (8), 2392-2402, 2019
3632019
Loss of TGF-β type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-α-, MSP-and HGF-mediated signaling networks
N Cheng, NA Bhowmick, A Chytil, AE Gorksa, KA Brown, R Muraoka, ...
Oncogene 24 (32), 5053-5068, 2005
3432005
Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer
AJ Walsh, RS Cook, HC Manning, DJ Hicks, A Lafontant, CL Arteaga, ...
Cancer research 73 (20), 6164-6174, 2013
3282013
The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling
DM Brantley-Sieders, G Zhuang, D Hicks, WB Fang, Y Hwang, JMM Cates, ...
The Journal of clinical investigation 118 (1), 64-78, 2008
3212008
Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance
JM Balko, RS Cook, DB Vaught, MG Kuba, TW Miller, NE Bhola, ...
Nature medicine 18 (7), 1052-1059, 2012
3122012
Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer
AJ Walsh, RS Cook, ME Sanders, L Aurisicchio, G Ciliberto, CL Arteaga, ...
Cancer research 74 (18), 5184-5194, 2014
3022014
Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy
G Zhuang, DM Brantley-Sieders, D Vaught, J Yu, L Xie, S Wells, ...
Cancer research 70 (1), 299-308, 2010
2712010
Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor β1
RS Muraoka, Y Koh, LR Roebuck, ME Sanders, D Brantley-Sieders, ...
Molecular and cellular biology, 2003
2662003
Dual role of transforming growth factor β in mammary tumorigenesis and metastatic progression
RS Muraoka-Cook, N Dumont, CL Arteaga
Clinical cancer research 11 (2), 937s-943s, 2005
2202005
The relationship between obesity and hypoferraemia in adults: a systematic review
HL Cheng, C Bryant, R Cook, H O'connor, K Rooney, K Steinbeck
obesity reviews 13 (2), 150-161, 2012
2102012
Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies
AB Hanker, AD Pfefferle, JM Balko, MG Kuba, CD Young, V Sánchez, ...
Proceedings of the National Academy of Sciences 110 (35), 14372-14377, 2013
2022013
Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer
DN Edwards, VM Ngwa, AL Raybuck, S Wang, Y Hwang, LC Kim, SH Cho, ...
The Journal of clinical investigation 131 (4), 2021
1942021
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20